9/13/2010

AstraZeneca signed a three-year research agreement with the University College London's Institute of Ophthalmology to discover and develop stem-cell-based drugs to treat diabetic retinopathy. "We're getting very keen on the whole area of regenerative medicines, and they will be part of our research development over the next few years," an AstraZeneca official said.

Related Summaries